Bruker Co. (BRKR) to Post Q1 2018 Earnings of $0.23 Per Share, William Blair Forecasts

Bruker Co. (NASDAQ:BRKR) – Stock analysts at William Blair reduced their Q1 2018 earnings estimates for shares of Bruker in a research note issued on Monday. William Blair analyst A. Murphy now expects that the medical research company will earn $0.23 per share for the quarter, down from their prior estimate of $0.24. William Blair also issued estimates for Bruker’s Q4 2018 earnings at $0.56 EPS, FY2018 earnings at $1.37 EPS, Q1 2019 earnings at $0.26 EPS, Q2 2019 earnings at $0.28 EPS, Q3 2019 earnings at $0.34 EPS, Q4 2019 earnings at $0.60 EPS, FY2019 earnings at $1.48 EPS and FY2020 earnings at $1.59 EPS.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, February 8th. The medical research company reported $0.51 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.02. The firm had revenue of $530.50 million for the quarter, compared to analysts’ expectations of $506.74 million. Bruker had a return on equity of 26.58% and a net margin of 4.45%. Bruker’s revenue was up 12.8% on a year-over-year basis. During the same quarter last year, the business posted $0.46 EPS.

BRKR has been the topic of a number of other research reports. JPMorgan Chase & Co. raised Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 price target on the stock in a research note on Friday, November 3rd. Citigroup lifted their target price on Bruker from $29.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd. Bank of America raised Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 target price on the stock in a research note on Friday, November 3rd. Zacks Investment Research raised Bruker from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research note on Wednesday, November 8th. Finally, Cowen reaffirmed a “hold” rating and set a $35.00 target price on shares of Bruker in a research note on Thursday, December 21st. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $32.29.

Bruker (NASDAQ BRKR) opened at $31.19 on Wednesday. The firm has a market capitalization of $4,889.33, a PE ratio of 25.76, a P/E/G ratio of 2.10 and a beta of 1.05. Bruker has a 12 month low of $21.83 and a 12 month high of $36.53. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60.

Several institutional investors have recently made changes to their positions in BRKR. Ameriprise Financial Inc. lifted its holdings in shares of Bruker by 296.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 98,231 shares of the medical research company’s stock valued at $2,833,000 after buying an additional 73,469 shares during the last quarter. Parametric Portfolio Associates LLC lifted its holdings in shares of Bruker by 8.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 183,958 shares of the medical research company’s stock valued at $5,305,000 after buying an additional 13,560 shares during the last quarter. Stifel Financial Corp acquired a new stake in shares of Bruker during the 2nd quarter valued at about $575,000. Royal Bank of Canada lifted its holdings in shares of Bruker by 11.1% during the 2nd quarter. Royal Bank of Canada now owns 70,842 shares of the medical research company’s stock valued at $2,043,000 after buying an additional 7,088 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Bruker by 0.5% during the 2nd quarter. State Street Corp now owns 1,407,941 shares of the medical research company’s stock valued at $40,605,000 after buying an additional 7,356 shares during the last quarter. Institutional investors and hedge funds own 64.78% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/14/bruker-co-brkr-to-post-q1-2018-earnings-of-0-23-per-share-william-blair-forecasts.html.

About Bruker

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Earnings History and Estimates for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply